Authors' objectives: Renal cell carcinoma is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years. This means that it is often diagnosed late, after it has spread to other parts of the body, and cannot be cured by surgery, which is the most effective treatment for kidney cancer. Lenvatinib is a new drug for the treatment of renal cell carcinoma. It is taken daily as a tablet. Some studies have shown lenvatinib may work best in combination with a drug that is already used for the treatment of renal cell carcinoma called everolimus. If lenvatinib with everolimus is licensed for use in the UK, it could be a new treatment option for patients with renal cell carcinoma. This may improve survival when current treatments have not worked.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/lenvatinib-in-combination-with-everolimus-for-advanced-or-metastatic-renal-cell-carcinoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)